A first technique for ameliorating bioactivity deterioration in fatty acid delivery includes retarding oxidation of fatty acids during manufacture, transportation, and storage of the fatty acid. A second technique for ameliorating bioactivity deterioration in fatty acid delivery includes enteric microencapsulation to avoid destruction of fatty acids in the stomach in favor of dissolving the fatty acids in the small intestines.

A first technique for ameliorating bioactivity deterioration in fatty acid delivery includes retarding oxidation of fatty acids during manufacture, transportation, and storage of the fatty acid. A second technique for ameliorating bioactivity deterioration in fatty acid delivery includes enteric microencapsulation to avoid destruction of fatty acids in the stomach in favor of dissolving the fatty acids in the small intestines.

Methods and compositions for treating and preventing medical conditions associated with the distribution, transport, and deiodination of thyroid hormone in the central nervous system (“CNS”), including but not limited to the brain and spinal cord are disclosed. In particular, methods and compositions for treating Allan Herndon Dudley Syndrome are disclosed.

Methods and compositions for treating and preventing medical conditions associated with the distribution, transport, and deiodination of thyroid hormone in the central nervous system (“CNS”), including but not limited to the brain and spinal cord are disclosed. In particular, methods and compositions for treating Allan Herndon Dudley Syndrome are disclosed.

The present invention relates to a benzimidazolone-based cinnamamide derivative as a TRPV1 antagonist and a pharmaceutical composition for treating or preventing pain containing the same as an active ingredient. The example compounds provided in one aspect of the present invention block the TRPV1 activation caused by capsaicin, a TRPV1 receptor activator, but induce an appropriate inhibition of about 20% to 80% of pH, thereby the compounds have effects of alleviating pain and effectively reducing side effects such as abnormal body temperature.

The present invention relates to a benzimidazolone-based cinnamamide derivative as a TRPV1 antagonist and a pharmaceutical composition for treating or preventing pain containing the same as an active ingredient. The example compounds provided in one aspect of the present invention block the TRPV1 activation caused by capsaicin, a TRPV1 receptor activator, but induce an appropriate inhibition of about 20% to 80% of pH, thereby the compounds have effects of alleviating pain and effectively reducing side effects such as abnormal body temperature.

The present invention relates to a benzimidazolone-based cinnamamide derivative as a TRPV1 antagonist and a pharmaceutical composition for treating or preventing pain containing the same as an active ingredient. The example compounds provided in one aspect of the present invention block the TRPV1 activation caused by capsaicin, a TRPV1 receptor activator, but induce an appropriate inhibition of about 20% to 80% of pH, thereby the compounds have effects of alleviating pain and effectively reducing side effects such as abnormal body temperature.

The present invention patent application relates essentially to an additive, the function of which is to enhance immunity, prevent various diseases and increase detoxification of the organism. The additive is composed of: 60 mcg of vitamin A; 4.5 mg of vitamin C; 1 mg of vitamin E; 3.4 mcg of selenium; 0.5 mg of copper; 0.7 mg of zinc; 0.23 mg of manganese; 3 mg of coenzyme Q10; 5 mg of pycnogenol; 0.13 mg of vitamin B2; 1.6 mg of vitamin B3; 0.13 mg of vitamin B6; 24 mcg of folic acid; 0.24 mcg of vitamin B12; 2 mg of glutathione; 100 mg of leucine; 20 mg of isoleucine; 20 mg of valine; 50 mg of glycine; 50 mg of taurine; 300 mg of glutamine; 60 mg of acetylcysteine; 50 mg of cysteine; 100 mg of methionine; 0.5 mg of vitamin B5; 2 mg of lycopene; and 4 mg of resveratrol.

The present invention patent application relates essentially to an additive, the function of which is to enhance immunity, prevent various diseases and increase detoxification of the organism. The additive is composed of: 60 mcg of vitamin A; 4.5 mg of vitamin C; 1 mg of vitamin E; 3.4 mcg of selenium; 0.5 mg of copper; 0.7 mg of zinc; 0.23 mg of manganese; 3 mg of coenzyme Q10; 5 mg of pycnogenol; 0.13 mg of vitamin B2; 1.6 mg of vitamin B3; 0.13 mg of vitamin B6; 24 mcg of folic acid; 0.24 mcg of vitamin B12; 2 mg of glutathione; 100 mg of leucine; 20 mg of isoleucine; 20 mg of valine; 50 mg of glycine; 50 mg of taurine; 300 mg of glutamine; 60 mg of acetylcysteine; 50 mg of cysteine; 100 mg of methionine; 0.5 mg of vitamin B5; 2 mg of lycopene; and 4 mg of resveratrol.

Infant formula compositions and methods for delivering at least one compound selected from nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, in combination with at least one of thiamine (vitamin B1), riboflavin (vitamin B2), niacin (vitamin B3), and pyridoxine (vitamin B6), to an infant human subject in need of said compound or compounds are provided.